Continuous Cardiac Monitoring.
Anytime, Anywhere.

Corsano Health B.V. is a health-tech company developing, producing and marketing medically certified continuous health monitoring devices. The Corsano brandname is derived from in corpore sano (in a healthy body).

Its first product, the Corsano CardioWatch is an essential part of a cardiac arrhythmia screening system that can, by providing a simple and effective method for continuous monitoring of the user’s heart rhythm, help identify the risk of a heart attack in an early stage. In its most extended version, the system consists of a bracelet plus a dedicated app on the user’s smartphone. The system can assist the user with maintaining a healthy lifestyle by providing immediate feedback on activity, sleep and heart rhythm data. Furthermore, smart analytics produce relevant data for timely detection of heart rhythm anomalies.

Corsano Health B.V. is medically certified complying with Annex IX (MDR) and EN-ISO 13485 standards. We are developing and manufacturing best-in-class remote vital health monitoring wearables that are both clinician and user friendly. We leverage strategic partners to develop, test and validate a medical wearable with reliable continuous measuring functions to detect and monitor heart, lung and mental disease.

Validated Data

Clinical evidence for multiple use cases. ISO13485 and EU-MDR certified


 Built in close collaboration with clinical professionals. 

Flexibility to develop custom solutions

Patient friendly

Battery life 8-15 days.
Ergonomic and aesthetic designs that stimulate continuous wear

Security & Privacy

Secure and Private Health Cloud, GDPR, Anonymization

EU-MDR CE Certified

The CardioWatch 287 is a medically certified wireless remote monitoring system intended for continuous collection of physiological data in home and healthcare settings. CardioWatch 287-1 is a CE medical device certified under EU-MDR standards. This includes heart rate, heart rate variability (R-R interval), respiration rate, activity and sleep. Data is transmitted wirelessly from the device via the application or gateway to a health cloud where it is stored and made available for further analysis.

The CardioWatch 287 can include the ability to notify healthcare professionals when physiological data fall outside selected parameters.

The high-quality patented PPG interface enables the device to accurately measure the following vital parameters:

  • Sleep (validated PPG-Based Sleep Staging – Jul. 2017)
  • A-Fib (CE Class IIa Certified algorithm Preventicus – May 2018)
  • Activity Type, Speed, Cadence (validated VSO ELAN – Nov. 2019)
  • Heart Rate (Validated CCN – Mar. 2021)
  • RR intervals (Validated CCN – Mar. 2021)
  • Respiration Rate (Haaglanden Clinics – Jun. 2021)
  • SPO2 (in development – Dec. 2021)
  • Core Body Temperature (in development – Oct. 2021)
  • Blood Pressure (in development Reinier de Graaf – Dec. 2021)


Addressable Markets


Diagnostic & remote medical monitoring 

Digital mental health & wellness

Contract Research Organizations


Hospital & ambulant patient monitoring

Remote monitoring & care, digital therapeutics, corporate well-being

Decentralized clinical trials for active pharmaceutical ingredients

Corsano’s offering is the basis of telehealth, for continuous monitoring of patients in multiple disease areas: cardiovascular diseases, stress related diseases, recovery, oncology etc.

During the pandemic, telehealth offered a bridge to care, and now offers a chance to reinvent virtual and hybrid virtual/in-person care models, with a goal of improved healthcare access, outcomes, and affordability.

McKinsey estimates that up to $250 billion of US healthcare spend could potentially be shifted to virtual or virtually enabled care. This step-change, borne out of necessity, was enabled by these factors:

  1. increased consumer willingness to use telehealth
  2. increased provider willingness to use telehealth
  3. regulatory changes enabling greater access and reimbursement

CardioWatch 287 is especially suited to take advantage of this trend.


Corsano has made “Cooperation” one of the core values upon which the company commits to base all its relationships. To be successful in business and life, a relationship has to be a two way street with give and take. At Corsano, we believe in cultivating good working relationships with our partners. We don’t limit ourselves to a select few, but always attempt to find the best possible partners. Corsano develops and manufactures medical wearables for research and continuous patient monitoring, that is our core business. Our open strategy is to connect to partner platforms and systems via APIs. We provide access to raw and processed data to partners enabling them to offer a variety of healthcare services. As such, we deal with hospitals, CROs, associations and companies worldwide.

Large Research Projects

We participate in Europe’s research and innovation challenges where we collaborate with researchers in consortia with partners. Corsano Health’s CardioWatch is the preferred choice to measure vital parameters, both in raw data acquisition as well as validation clinical trials. We offer co-development of new features and algorithms to increase success of consortia applications. Recent awarded projects:


Project for a validated, energetically autonomous module that harvests from any source of light through a novel microchip, the PMIC developed by Nowi. Narrow-Band IoT chip (NB-IoT) will be integrated into the module for ubiquitous connectivity.


Clinical validation of a comprehensive care solution (‘WATCH-IT’) enabling 24/7 monitoring of cardio-respiratory function in patients at risk of cardiovascular (CV) events. Collaboration with Preventicus, Oslo University Hospital (OUH) and University of Gothenburg (GU).


Innovative solution to improve recognition and implementation of resuscitation assistance for patients with Cardiac Arrest. Development project in colaboration with RadboudMC to recognize Cardiac Arrest with CardioWatch 287 and alert emergency services.